Gland Pharma has received confirmation regarding the dematerialization of shares for the quarter ended December 31, 2025 (Q3 2026). The confirmation was received from MUFG Intime India Private Limited, the Registrar and Share Transfer Agent. This confirms that all securities received for dematerialization have been duly processed and verified as per regulatory guidelines.
Dematerialization Confirmation
Gland Pharma announced the receipt of a Confirmation Certificate from MUFG Intime India Private Limited on January 5, 2026, pertaining to the dematerialization requests processed during the quarter ended December 31, 2025 (Q3 2026).
Details of Compliance
The certificate confirms that all securities received from depository participants for dematerialization during the specified quarter have been duly processed and approved. Furthermore, the Registrar and Share Transfer Agent verified that the security certificates received were mutilated and canceled after due verification, ensuring compliance with regulatory requirements.
No Rematerialization Requests
MUFG Intime India Private Limited stated that they did not receive any requests for dematerialization or rematerialization of shares during the review period. This confirmation ensures adherence to established regulatory standards and transparency in securities processing.
Source: BSE
